background
due
emerg
drug
resist
herp
simplex
viru
type
research
tri
find
method
treat
herp
simplex
viru
type
infect
probiot
bacteria
effect
macrophag
activ
may
antivir
activ
object
studi
aim
verifi
direct
effect
lactobacillu
rhamnosu
probiot
bacterium
comparison
escherichia
coli
nonprobiot
one
infect
determin
effect
macrophag
activ
vitro
elimin
infect
method
bacteria
introduc
infect
vero
cell
effect
examin
use
mtt
plaqu
assay
determin
macrophag
activ
vitro
infect
cell
expos
bacteria
macrophag
viabil
examin
mtt
method
tumor
necrosi
factor
alpha
interferongamma
nitric
oxid
assess
perform
use
elisa
method
result
signific
increas
viabil
macrophag
observ
p
presenc
lactobacillu
rhamnosu
infect
compar
escherichia
coli
nonprobiot
bacterium
howev
tumor
necrosi
factor
concentr
produc
escherichia
colitr
cell
significantli
higher
lactobacillu
rhamnosustr
cell
p
interferongamma
product
differ
group
treat
escherichia
coli
lactobacillu
rhamnosu
conclus
result
studi
indic
lactobacillu
rhamnosu
enhanc
macrophag
viabil
elimin
activ
effect
compar
nonprobiot
escherichia
coli
also
seem
receptor
occup
macrophag
site
decreas
infect
studi
bacteria
vitro
studi
effect
probiot
bacterium
lactobacillu
rhamnosu
herp
simplex
viru
type
herp
simplex
caus
two
type
infect
initi
infect
often
asymptomat
involv
epitheli
cell
latent
sensori
nerv
ganglia
infect
individu
latent
virus
activ
differ
stress
condit
instanc
sunshin
hormon
chang
fever
appear
cold
sore
agent
mani
diseas
gingivostomat
sore
throat
pharyng
herpet
whitlow
keratoconjunct
herp
enceph
mening
immunosuppress
patient
chronic
destruct
process
specif
nonspecif
defens
mechan
import
host
genet
background
macrophag
nk
cell
tcell
antibodi
import
factor
defens
macrophag
activ
also
reduc
infect
viru
antivir
drug
includ
acyclovir
vidarabin
famciclovir
valacyclovir
pencyclovir
wide
use
treatment
infect
nowaday
occurr
mutat
viral
dna
polymeras
thymidin
kinas
led
increas
drug
resist
nucleosid
analog
acyclovir
find
appropri
altern
research
suggest
seek
new
chemic
plant
sourc
therapi
infect
consid
role
specif
nonspecif
host
defens
therapi
work
strengthen
activ
innat
specif
immun
system
compon
coordin
oper
macrophag
antiherpet
respons
occur
first
hour
viru
invas
first
defens
line
product
secret
cytokin
type
interferon
ifn
tumor
necrosi
factor
tnf
subsequ
produc
therebi
result
natur
killer
cell
macrophag
activ
product
activ
oxygen
radic
ro
auxiliari
mechan
improv
antivir
respons
macrophag
receptor
molecul
lipopolysaccharid
mannos
unmethyl
cpg
repeat
bacteria
signal
result
combin
factor
increas
secret
wide
rang
cytokin
strengthen
innat
immun
system
activ
specif
immun
system
especi
cell
pathogen
virus
among
launch
variou
activ
macrophag
includ
antimicrobi
activ
caus
erad
intracellular
pathogen
macrophag
activ
one
first
step
prevent
viru
prolifer
hiv
hsv
vzv
infect
cell
also
antigen
process
present
lymphocyt
macrophag
induc
cellmedi
immun
induct
macrophag
inflammatori
respons
also
innat
immun
defens
system
differ
task
kill
infect
cell
tumor
cell
parasit
pathogen
antivir
effect
variou
viral
infect
also
document
probiot
bacteria
lactobacillu
bifidobacterium
typic
ferment
dairi
food
human
anim
digest
tract
balanc
immun
system
increas
specif
nonspecif
immun
respons
import
immunomodulatori
bacteria
bodi
defens
pathogen
virus
hiv
vzv
variou
studi
shown
lactobacillu
rhamnosu
strain
gg
speci
probiot
bacteria
benefici
effect
treat
rotaviru
gastroenter
infant
sever
studi
vitro
system
anim
model
human
suggest
probiot
enhanc
specif
nonspecif
immun
respons
studi
demonstr
consumpt
lactic
acid
bacteria
guinea
pig
antiinfluenza
effect
also
take
cfuml
lactic
acid
bacteria
decreas
genit
herp
complic
caus
anoth
studi
effect
probiot
bacteria
prevent
treatment
viral
diarrhea
caus
rotaviru
astroviru
caliciviru
enter
adenoviru
coronaviru
review
help
role
probiot
bacteria
limit
viral
diarrhea
document
vitro
studi
demonstr
probiot
bacteria
increas
antivir
respons
vesicular
stomat
viru
vsv
activ
macrophag
emerg
antivir
drug
resist
observ
make
necessari
find
altern
treat
infect
consid
import
role
macrophag
elimin
viral
infect
effect
role
probiot
bacteria
remov
viral
infect
includ
hsv
studi
aim
investig
direct
effect
lactobacillu
rhamnosu
probiot
bacterium
effect
macrophag
activ
vitro
elimin
infect
way
possibl
use
probiot
inhibit
infect
would
scientif
proven
altern
treatment
lyophil
standard
strain
lactobacilli
rhamnosu
ptcc
e
coli
ptcc
provid
iranian
research
organ
scienc
technolog
tehran
iran
lactobacilli
rhamnosu
cultur
log
phase
growth
lcystein
hcl
supplement
man
rogosa
sharp
mr
broth
himedia
india
anaerob
condit
overnight
order
isol
singl
bacteri
coloni
harvest
broth
transfer
mr
agar
himedia
india
incub
describ
condit
hour
maximum
number
bacteria
introduc
antivir
assay
determin
highest
number
bacteria
cytotox
macrophag
cell
line
data
shown
valu
determin
cfuml
strain
prepar
cfuml
viabl
bacteria
stimul
experi
isol
coloni
suspend
pb
optic
densiti
od
measur
spectrophotomet
nm
coloni
concentr
determin
via
intern
mcfarland
standard
od
comparison
percentag
adher
bacteria
determin
coincub
bacteria
macrophag
cell
line
minut
humidifi
atmospher
co
nonadher
bacteria
remov
cell
cultur
wash
twice
pb
cell
harvest
percentag
adher
bacteria
determin
agar
plate
count
serial
dilut
suspens
plate
mr
agar
order
prepar
inactiv
bacteri
suspens
cultur
frozen
cfuml
count
thaw
boil
water
cycl
also
e
coli
grown
log
phase
growth
emb
agar
merck
germani
overnight
isol
lip
lesion
patient
confirm
neutral
test
use
guinea
pig
serum
nih
usa
monoclon
antibodi
hsv
glycoprotein
g
grown
titer
ml
vero
cell
line
mainten
medium
dulbecco
modifi
eagl
growth
medium
dmem
sigma
supplement
fetal
bovin
serum
gibco
germani
vv
sodium
bicarbon
uml
penicillin
streptomycin
sulphat
amphotericin
b
viru
store
use
antivir
assay
viru
plaqueform
unit
per
ml
use
murin
monocytemacrophag
cell
line
cell
obtain
pasteur
institut
tehran
iran
grown
confluenc
rpmi
media
gibco
australasia
contain
fetal
bovin
serum
fb
supplement
streptomycin
iuml
penicillin
tissu
cultur
flask
nunc
denmark
atmospher
co
also
confluent
vero
african
green
monkey
kidney
cell
razi
institut
hesarak
iran
prepar
dmem
supplement
fetal
calf
serum
vero
cell
mainten
dmem
medium
use
supplement
fetal
calf
serum
order
evalu
cell
viabil
trypan
blue
dye
merck
germani
exclus
method
perform
possibl
inhibitori
effect
studi
bacteria
investig
use
plaqu
reduct
assay
previous
describ
phosphat
buffer
salin
pb
wash
confluent
vero
cell
plate
nunc
denmark
treat
mainten
medium
contain
plate
nunc
denmark
treat
first
mainten
medium
contain
cfuml
live
bacteri
debri
suspens
e
coli
l
rhamnosu
min
min
anoth
seri
experi
describ
condit
cell
first
expos
viru
bacteria
also
simultan
expos
bacteria
viru
remov
treatment
monolay
infect
pfuml
one
hour
subsequ
monolay
overlaid
carboxymethyl
cellulos
cmc
mainten
medium
incub
co
four
day
control
seri
experi
includ
uninfect
cell
monolay
virusinfect
treat
untreat
cell
bacteria
viru
plaqu
form
cell
fix
methanol
min
stain
crystal
violet
solut
mtt
assay
dimethyl
yl
tetrazolium
bromid
sigma
usa
use
assess
live
cell
accord
measur
activ
mitochondri
metabol
function
assay
abl
indic
potenti
benefici
effect
antivir
agent
briefli
incub
period
hour
presenc
co
plate
contain
serial
dilut
cell
suspens
cell
concentr
cellml
well
wash
readi
mtt
dye
ad
plate
incub
hour
period
content
centrifug
min
rpm
supernat
remov
cell
suspend
dmso
optic
densiti
well
determin
nm
use
elisa
reader
cellml
cell
incub
plate
presenc
co
hour
cfu
ml
live
andor
bacteri
debri
suspens
ad
separ
well
plate
prior
pb
wash
cell
remain
min
adher
bacteria
cell
plate
incub
presenc
co
anoth
hour
cytokin
releas
next
stage
supernat
cell
treat
bacteria
transfer
plate
contain
infect
vero
cell
min
percentag
viabl
cell
measur
use
mtt
test
describ
well
contain
noninfect
vero
cell
free
supernat
cell
treat
bacteria
consid
control
plate
cellml
cell
inocul
cfuml
live
andor
bacteri
debri
suspens
min
infect
min
anoth
seri
experi
cell
infect
min
inocul
cfuml
live
andor
bacteri
debri
suspens
min
plate
incub
presenc
co
hour
percentag
metabol
activ
cell
determin
via
mtt
test
describ
well
contain
neither
viru
bacterium
consid
neg
control
prior
perform
mtt
test
supernat
cell
collect
measur
level
measur
concentr
level
releas
measur
use
griess
reaction
supernat
incub
cellml
cell
cell
treat
l
rhamnosu
inactiv
l
rhamnosu
ecoli
inactiv
e
coli
presenc
co
hour
ad
elisa
plate
separ
modifi
griess
reagent
merck
germani
min
incub
room
temperatur
absorb
nm
measur
concentr
calcul
use
nano
standard
curv
level
detect
use
commerci
enzymelink
immunosorb
assay
elisa
kit
bender
medsystem
usa
accord
manufactur
instruct
supernat
incub
cellml
cell
cell
treat
l
rhamnosu
inactiv
l
rhamnosu
e
coli
inactiv
e
coli
presenc
co
hour
ad
elisa
plate
separ
statist
analys
perform
use
statist
packag
social
scienc
spss
version
softwar
chicago
il
usa
differ
two
group
l
rhamnosu
e
coli
test
use
mannwhitney
test
cell
use
control
pvalu
less
equal
consid
statist
signific
compar
vero
cell
control
significantli
lower
number
plaqu
detect
vero
cell
cultur
treat
l
rhamnosu
either
pre
post
infect
respect
statist
similar
reduct
plaqu
observ
vero
cell
expos
e
coli
tabl
shown
fig
supernat
pretreat
macrophag
cell
live
andor
inact
l
rhamnosu
significantli
increas
vero
cell
viabil
comparison
cell
infect
viru
p
howev
e
coli
treatment
caus
lower
vero
cell
viabil
differ
signific
p
shown
fig
significantli
increas
viabil
cell
observ
l
rhamnosu
treatment
cell
pre
postinfect
versu
nontreat
cell
e
colitr
cell
p
coincub
cell
suspens
either
live
inact
l
rhamnosu
e
coli
stimul
macrophag
produc
tabl
e
coli
caus
significantli
higher
product
compar
l
rhamnosu
p
remark
induct
product
observ
cell
expos
live
e
coli
suspens
pre
post
infect
well
inact
e
coli
p
effect
seen
l
rhamnosu
live
inact
suspens
l
rhamnosu
e
coli
stimul
secret
infect
cell
discuss
clinic
intervent
studi
identifi
specif
probiot
antivir
effect
via
shorten
infecti
period
decreas
risk
certain
viral
infect
best
find
benefici
influenc
probiot
viral
diarrhea
infant
children
studi
anti
effect
select
vagin
lactobacillu
strain
l
brevi
l
salivariu
l
plantarum
conti
et
al
demonstr
inhibitori
effect
live
bacteri
cell
sever
mechan
includ
interfer
earli
step
viru
replic
bindingentri
product
lactic
acid
hydrogen
peroxid
direct
antivir
effect
also
two
separ
report
demonstr
protect
effect
variou
lactic
acid
bacteria
vsvinfect
porcin
epitheli
macrophag
cell
line
regard
proven
antivir
effect
probiot
strain
research
attempt
creat
appropri
protocol
treat
prevent
infect
decid
test
probiot
bacterium
candid
purpos
studi
evalu
vitro
effect
l
rhamnosu
probiot
bacterium
directli
infect
influenc
stimul
releas
product
proinflammatori
cytokin
follow
l
rhamnosu
activ
murin
monocyt
macrophag
cell
line
result
clearli
demonstr
l
rhamnosu
exposur
enhanc
viabil
cell
line
remark
comparison
result
report
ivec
et
al
viabil
vsv
infect
cell
line
caus
viabil
increas
due
differ
cell
line
vsv
infecti
capac
versu
probiot
speci
two
studi
also
detect
protect
effect
live
bacteria
inact
bacteria
exposur
viral
infect
macrophag
find
consist
ivec
et
al
report
mechan
involv
protect
effect
probiot
bacteria
viru
particl
competit
cell
surfac
attach
alreadi
proven
vitro
report
feasibl
mechan
protect
cell
case
vsv
infect
preserv
cpg
motif
bacteri
dna
inactiv
bacteria
report
suppress
apoptot
pathway
enhanc
cell
viabil
studi
demonstr
higher
viabil
infect
macrophag
cell
treat
l
rhamnosu
compar
e
coli
treatment
although
reason
unclear
one
explan
lower
cell
viabil
case
e
coli
exposur
compar
l
rhamnosu
relat
increas
product
induc
e
coli
caus
cell
apoptosi
show
product
induc
e
coli
exposur
preand
infect
cell
compar
l
rhamnosu
presenc
lipopolysaccharid
cell
wall
e
coli
potenti
stimul
tnf
releas
increas
viabil
infect
vero
cell
supernat
cell
expos
l
rhamnosu
might
result
product
proinflammatori
cytokin
suppress
prolifer
releas
anoth
antivir
mechan
also
previous
report
fact
signific
increas
releas
report
coincub
macrophag
expos
probiot
bacteria
presenc
howev
ivec
et
al
state
import
factor
stimul
releas
studi
cell
coincub
live
inact
l
rhamnosu
e
coli
capabl
induc
product
concentr
depend
mediat
lower
previou
report
howev
report
probiot
bacteria
appli
exogen
conclud
simultan
presenc
probiot
bacteria
might
necessari
product
high
level
case
inact
bacteria
cell
wall
compon
peptidoglycan
lipoteicho
acid
cpg
motif
induc
product
cell
howev
level
lower
induc
live
bacteri
exposur
conclus
l
rhamnosu
abl
induc
sever
antivir
effect
might
differ
mechan
includ
compet
viru
cell
surfac
attach
increas
macrophag
viabil
follow
stimul
proinflammatori
respons
thu
result
suggest
futur
vivo
evalu
l
rhamnosu
increas
immun
defens
cell
probabl
candid
infect
cotherapi
